Windtree Therapeutics, a Nasdaq-listed biotech firm, plans to acquire up to $700 million in BNB, the fifth-largest cryptocurrency, as it seeks to enhance its balance sheet. Following a recent all-time high price of $808 for BNB, the company is raising $520 million to facilitate these purchases. This will be achieved through a $500 million equity line of credit and a separate $20 million stock purchase agreement. Windtree has partnered with crypto exchange Kraken to provide custody and trading services for its BNB holdings. The firm’s CEO emphasized the necessity of securing additional funding for the BNB acquisition strategy, which is part of a trend where publicly traded companies are increasingly investing in cryptocurrencies beyond Bitcoin. Windtree's stock has fluctuated, though it rose 162% over the past month despite a current decline of about 5%. Other companies, such as Nano Labs, are also making significant investments in BNB.

Source 🔗